|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
26
|
|
pubmed:dateCreated |
2011-6-30
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
pubmed-author:BaurainJean-FrançoisJF,
pubmed-author:BondarenkoIgorI,
pubmed-author:ChenTai-TsangTT,
pubmed-author:DavidsonNevilleN,
pubmed-author:FrancisStephenS,
pubmed-author:GarbeClausC,
pubmed-author:GasconPereP,
pubmed-author:GrobJean-JacquesJJ,
pubmed-author:HarmankayaKaanK,
pubmed-author:HauschildAxelA,
pubmed-author:HoosAxelA,
pubmed-author:HumphreyRachelR,
pubmed-author:IbrahimRamyR,
pubmed-author:LebbeCelesteC,
pubmed-author:LotemMichalM,
pubmed-author:M DJeffrey WeberJW,
pubmed-author:MaioMicheleM,
pubmed-author:MillerWilson HWHJr,
pubmed-author:O'DayStevenS,
pubmed-author:RichardsJonJ,
pubmed-author:RobertCarolineC,
pubmed-author:TestoriAlessandroA,
pubmed-author:ThomasLucL,
pubmed-author:WolchokJedd DJD
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
30
|
|
pubmed:volume |
364
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2517-26
|
|
pubmed:dateRevised |
2011-10-13
|
|
pubmed:meshHeading |
pubmed-meshheading:21639810-Antibodies, Monoclonal,
pubmed-meshheading:21639810-Antineoplastic Agents, Alkylating,
pubmed-meshheading:21639810-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21639810-Dacarbazine,
pubmed-meshheading:21639810-Disease Progression,
pubmed-meshheading:21639810-Double-Blind Method,
pubmed-meshheading:21639810-Female,
pubmed-meshheading:21639810-Humans,
pubmed-meshheading:21639810-Kaplan-Meier Estimate,
pubmed-meshheading:21639810-Liver Function Tests,
pubmed-meshheading:21639810-Male,
pubmed-meshheading:21639810-Melanoma,
pubmed-meshheading:21639810-Middle Aged,
pubmed-meshheading:21639810-Proportional Hazards Models
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
|
|
pubmed:affiliation |
Institute Gustave, Roussy, Villejuif, France.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
